Pavmed INC. (PAVM) — SEC Filings

Overview

Pavmed INC. (PAVM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: PAVmed Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition, and making Regulation FD disclosures. The filing includes financial statements and exhibits, with the company's mailing and business address listed as 360 Madison Avenue, New York, NY 10017.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for Pavmed INC. is neutral.

Filing Type Overview

Pavmed INC. (PAVM) has filed 32 8-K, 5 10-Q, 4 DEF 14A, 2 DEFA14A, 2 10-K, 2 SC 13D/A, 3 SC 13G with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• PAVmed Inc. Files 8-K: Financials & Reg FD Update — 8-K · Mar 30, 2026 Risk: medium
  PAVmed Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition, and making Regulation FD disclosures. The filing inc
• 8-K Filing — 8-K · Dec 30, 2025
• 8-K Filing — 8-K · Dec 5, 2025
• PAVmed Inc. Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  PAVmed Inc. filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosure
• PAVmed Swings to Loss Amidst Revenue Collapse, Cash Position Improves — 10-Q · Nov 12, 2025 Risk: high
  PAVmed Inc. reported a net income attributable to common stockholders of $(6,328) thousand for the three months ended September 30, 2025, a significant decrease
• PAVmed Seeks Reverse Split to Boost Share Price, Avoid Nasdaq Delisting — DEF 14A · Oct 31, 2025 Risk: high
  PAVmed Inc. (PAVM) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-10 and 1-for-30, along with a reduction in authorized comm
• PAVmed Inc. Files 8-K Report — 8-K · Sep 11, 2025 Risk: low
  On September 11, 2025, PAVmed Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific fi
• PAVmed Inc. Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  PAVmed Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures
• PAVmed Swings to Profit on Investment Gains, Revenue Plummets — 10-Q · Aug 14, 2025 Risk: high
  PAVmed Inc. reported a significant turnaround in its financial performance for the six months ended June 30, 2025, achieving a net income attributable to PAVmed
• PAVmed Inc. Relocates Principal Executive Offices — 8-K · Jul 30, 2025 Risk: low
  PAVmed Inc. filed an 8-K on July 30, 2025, reporting an event that occurred on July 29, 2025. The filing indicates a change in the company's principal executive
• PAVmed Inc. Files Material Definitive Agreement 8-K — 8-K · Jun 24, 2025 Risk: medium
  On June 23, 2025, PAVmed Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits. The com
• PAVmed Inc. Files 8-K on Corporate Governance and Compensation — 8-K · Jun 18, 2025 Risk: medium
  PAVmed Inc. filed an 8-K on June 18, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain of
• PAVmed Inc. Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  PAVmed Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and
• PAVmed Inc. Files Proxy Statement Addendum — DEFA14A · May 9, 2025 Risk: low
  PAVmed Inc. filed a Definitive Additional Materials filing (DEFA14A) on May 9, 2025. This filing relates to the company's proxy statement and is subject to Sect
• PAVmed Inc. DEF 14A: Executive Compensation Details — DEF 14A · Apr 30, 2025 Risk: medium
  PAVmed Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on
• PAVmed Inc. Appoints BDO USA, LLP as New Auditor — 8-K · Apr 25, 2025 Risk: low
  On April 23, 2025, PAVmed Inc. filed an 8-K report detailing changes in its certifying accountant. The company has appointed BDO USA, LLP as its new independent
• PAVmed Inc. Files 8-K for Material Agreement — 8-K · Apr 17, 2025 Risk: medium
  On April 17, 2025, PAVmed Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, incorporated in Delaware wit
• PAVmed Inc. Files 8-K Report — 8-K · Apr 11, 2025 Risk: low
  PAVmed Inc. filed an 8-K report on April 11, 2025, to disclose information regarding other events and financial statements. The filing does not contain specific
• PAVmed Inc. Files 8-K on Financials — 8-K · Mar 25, 2025 Risk: low
  On March 25, 2025, PAVmed Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regula
• PAVmed Inc. Files 2024 10-K — 10-K · Mar 24, 2025 Risk: medium
  PAVmed Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as PAXmed Inc., is incorpo
• PAVmed Inc. Files 8-K Report — 8-K · Mar 10, 2025 Risk: low
  On March 5, 2025, PAVmed Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or d
• PAVmed Inc. Reports Unregistered Equity Sales — 8-K · Feb 21, 2025 Risk: medium
  On February 18, 2025, PAVmed Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates the issuance of Series Z Warrants
• PAVmed Inc. Files 8-K Report — 8-K · Feb 18, 2025 Risk: low
  PAVmed Inc. filed an 8-K report on February 18, 2025, detailing events that occurred on February 14, 2025. The filing includes information on "Other Events" and
• PAVmed Inc. Files 8-K on Delisting Concerns — 8-K · Jan 24, 2025 Risk: high
  PAVmed Inc. filed an 8-K on January 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing also covers unregistere
• PAVmed Inc. Files 8-K: Delisting Notice, Equity Sales, Bylaw Changes — 8-K · Jan 21, 2025 Risk: high
  PAVmed Inc. filed an 8-K on January 21, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, unregistered sales of equity securi
• PAVmed Inc. Files 8-K with Corporate Updates — 8-K · Jan 15, 2025 Risk: low
  On January 15, 2025, PAVmed Inc. filed an 8-K report detailing several key events. The company announced amendments to its Articles of Incorporation and Bylaws,
• PAVmed Inc. Files Proxy Materials — DEFA14A · Jan 7, 2025 Risk: low
  PAVmed Inc. filed a Definitive Additional Materials proxy statement on January 7, 2025. This filing is related to the company's proxy materials and does not app
• PAVmed Inc. Amends Lucid Diagnostics Stake Filing — SC 13D/A · Dec 12, 2024 Risk: medium
  PAVmed Inc. filed an amendment (No. 4) to its Schedule 13D on December 12, 2024, concerning its beneficial ownership of Lucid Diagnostics Inc. common stock. The
• PAVmed Inc. Files Definitive Proxy Statement — DEF 14A · Dec 6, 2024 Risk: low
  PAVmed Inc. filed its definitive proxy statement (DEF 14A) on December 6, 2024, for its fiscal year ending December 31, 2024. The filing, which is not subject t
• PAVmed Inc. Enters Material Definitive Agreement — 8-K · Nov 29, 2024 Risk: medium
  On November 22, 2024, PAVmed Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an undisclosed lender. This agreement creates
• PAVmed Inc. Files 8-K on Equity Sales and Security Holder Rights — 8-K · Nov 21, 2024 Risk: medium
  On November 15, 2024, PAVmed Inc. entered into a material definitive agreement related to unregistered sales of equity securities. This filing also addresses ma
• SC 13G Filing — SC 13G · Nov 14, 2024
• PAVmed Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: medium
  PAVmed Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the year. Key financial da
• SC 13G Filing — SC 13G · Sep 23, 2024
• PAVmed Inc. Appoints New CMO, Completes Acquisition — 8-K · Sep 16, 2024 Risk: medium
  On September 10, 2024, PAVmed Inc. announced the departure of its Chief Medical Officer, Dr. Brian Smith, and the appointment of Dr. Jessica Chen as the new Chi
• PAVmed Inc. Files 8-K on Financials — 8-K · Aug 13, 2024 Risk: low
  On August 13, 2024, PAVmed Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and ex
• PAVmed Inc. Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  PAVmed Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as PAXmed Inc., is involved in the surgical and medical instruments
• PAVmed Inc. Files 8-K on Security Holder Votes and Financials — 8-K · Jun 20, 2024 Risk: low
  On June 20, 2024, PAVmed Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing include
• PAVmed Inc. Files 8-K on Financials and Operations — 8-K · May 14, 2024 Risk: medium
  PAVmed Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as providing Regulation FD disclosures and fin
• PAVmed Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  PAVmed Inc. (PAVM) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. PAVmed Inc. filed a 10-Q report for the period ending March 31, 2024. The filin
• PAVmed Inc. Files 8-K on Security Holder Rights — 8-K · May 7, 2024 Risk: medium
  On May 1, 2024, PAVmed Inc. entered into a material definitive agreement related to its security holders. The company, incorporated in Delaware with its princip
• PAVmed Inc. Files 8-K Report — 8-K · May 1, 2024 Risk: low
  On April 30, 2024, PAVmed Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific fi
• PAVmed Inc. Announces Annual Meeting of Stockholders on June 20, 2024 — DEF 14A · Apr 29, 2024 Risk: low
  PAVmed Inc. (PAVM) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. PAVmed Inc. will hold its Annual Meeting of Stockholders on June 20, 2024,
• PAVmed Inc. Files 8-K for Material Definitive Agreement — 8-K · Apr 26, 2024 Risk: medium
  On April 25, 2024, PAVmed Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreemen
• PAVmed Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 25, 2024 Risk: medium
  PAVmed Inc. (PAVM) filed a Annual Report (10-K) with the SEC on March 25, 2024. PAVmed Inc. filed its annual report on Form 10-K for the fiscal year ended Decem
• PAVmed Inc. Files 8-K: Material Definitive Agreement — 8-K · Mar 14, 2024 Risk: medium
  On March 12, 2024, PAVmed Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. This event also constitutes a Ma
• PAVmed Inc. Files 8-K Regarding Delisting Concerns — 8-K · Mar 8, 2024 Risk: high
  PAVmed Inc. filed an 8-K on March 7, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as PAXmed
• PAVmed Amends Lucid Diagnostics Stake — SC 13D/A · Feb 20, 2024 Risk: low
  PAVmed Inc. filed an SC 13D/A Amendment No. 3 on February 20, 2024, regarding its ownership in Lucid Diagnostics Inc. The filing indicates PAVmed Inc. holds Com
• PAVmed Reports Asset Action & Security Holder Rights Modification — 8-K · Feb 16, 2024 Risk: medium
  PAVmed Inc. filed an 8-K on February 16, 2024, reporting events from February 15, 2024, under Item 2.01 (Completion of Acquisition or Disposition of Assets), It
• SC 13G Filing — SC 13G · Feb 14, 2024

Risk Profile

Risk Assessment: Of PAVM's 45 recent filings, 6 were flagged as high-risk, 20 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Pavmed INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $5 thousand
• Net Income: $(6,328) thousand
• EPS: $(0.29)
• Debt-to-Equity: N/A
• Cash Position: $3,103 thousand
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Lishan Aklog, M.D.
• Dennis McGrath
• Dr. Brian Smith
• Dr. Jessica Chen

Industry Context

PAVmed Inc. operates in the medical technology sector, focusing on diagnostic and therapeutic solutions. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies often rely on strategic partnerships, subsidiary development, and external financing to bring innovative products to market.

Top Tags

filing (10) · sec-filing (8) · corporate-governance (7) · financials (6) · financial-reporting (4) · 8-K (4) · 8-k (4) · material-agreement (4) · proxy-statement (4) · equity-sale (4)

Key Numbers

• Net income (loss) attributable to PAVmed Inc. common stockholders: $(6,328) thousand — Q3 2025, a significant decrease from $64,316 thousand in Q3 2024
• Revenue: $5 thousand — Q3 2025, a drastic drop from $996 thousand in Q3 2024
• Cash: $3,103 thousand — As of September 30, 2025, an increase from $1,185 thousand at December 31, 2024
• Net cash flows provided by financing activities: $5,590 thousand — Nine months ended September 30, 2025, contributing to increased cash balance
• Total operating expenses: $4,849 thousand — Q3 2025, a decrease from $12,574 thousand in Q3 2024
• Net income (loss) per share attributable to PAVmed Inc. common stockholders – basic: $(0.29) — Q3 2025, compared to $6.43 in Q3 2024
• Common shares outstanding: 23,053,498 — As of September 30, 2025, an increase from 11,198,977 shares at December 31, 2024
• Senior Secured Convertible Notes - at fair value: $6,900 thousand — As of September 30, 2025, a decrease from $29,100 thousand at December 31, 2024
• Reverse Stock Split Ratio: 1-for-10 to 1-for-30 — Range of proposed reverse stock split ratios for PAVM common stock
• Current Authorized Common Stock: 250,000,000 shares — Number of shares PAVM is currently authorized to issue
• Proposed Authorized Common Stock: 25,000,000 shares — Number of shares PAVM proposes to be authorized to issue after reduction
• Nasdaq Minimum Bid Price: $1 — Required closing bid price for continued listing on Nasdaq Capital Market
• Nasdaq Non-Compliance Notification Date: January 23, 2025 — Date PAVM received notice of non-compliance with Nasdaq's $1 bid price rule
• Nasdaq Compliance Deadline: January 19, 2026 — Extended deadline for PAVM to regain compliance with Nasdaq's $1 bid price rule
• Record Date for Special Meeting: October 23, 2025 — Date for determining stockholders entitled to vote at the Special Meeting

Related Companies

LUCD

Frequently Asked Questions